Honasa buys 58% of Fluence Pharma for Rs 135 Cr, launches Honasa Health for D2C wellness play

Mamaearth parent enters the Rs 16,000 Cr nutraceuticals market via Fluence Pharma, acquiring 58% at Rs 135 Cr EV with the remaining 42% over 5-7 years. Fluence brings 3,000+ dermatologist relationships, hair/skin supplement brands (Hair Fact, Skin Fact), Rs 40 Cr FY26 revenue and 20%+ EBITDA margins.

— Source publishedTue, 23 Jun, 2026, 19:43 IST·First seen Tue, 23 Jun, 2026, 19:50 IST·Source Entrackr · Newsletter

What happened

Honasa Consumer acquires 58% of nutraceuticals firm Fluence Pharma at Rs 135 Cr EV, with remaining 42% over 5-7 years. Forms Honasa Health subsidiary to enter

Key facts

  • Rs 135 Cr enterprise value
  • 58% stake
  • 42% remaining over 5-7 years
  • Rs 40 Cr FY26 revenue
  • 20%+ EBITDA margin
  • 3,000+ dermatologists
  • Rs 16,000 Cr nutraceuticals market
  • 70% revenue from hair products

Why this matters

The staggered 58%-now / 42%-over-5-7-years structure aligns founder incentives while letting Honasa consolidate revenue immediately and de-risk integration—a template worth studying for category-extension M&A in regulated wellness adjacencies.

Also reported by